What type of study is this?

This is a Human Clinical Trial study.

What question did this study set out to answer?

Assess tolerability and safety of telmisartan in hypertensive patients intolerant to ACE-I due to cough.

March 14, 2026European Respiratory Journal

Cough among hypertensive patients treated with angiotensin convertase inhibitors. Reduction of its frequency by substitution of angiotensin convertase inhibitor with angiotensin receptor blocker. Results of non-interventional, observational postmarketing study

View Full Paper

Ask AI

Bookmark

Authors

TLT LietzBayer (United States)MWMichal WronkaBayer (United States)JKJ KozielskiMedical University of Silesia

Discussion

Member takes

Implication

Observational study shows that substituting ACE-I with telmisartan significantly reduces dry cough in hypertensive patients, indicating improved tolerability.

Key Points

Assess tolerability and safety of telmisartan in hypertensive patients intolerant to ACE-I due to cough.
Multi-center, non-controlled, observational study
2498 hypertensive patients enrolled
Cough frequency measured before and after substitution of ACE-I with telmisartan
Initial cough frequency was 74.2%, reduced to 2.92% after approximately 3 months
Significant correlation between cough intensity and ACE-I dose
Efficacy of telmisartan was lower in patients with asthma, bronchitis, and gastric reflux

Cite This Study

Lietz et al. (2011) studied this question.

synapsesocial.com/papers/69b4ada918185d8a398013b7 https://doi.org/10.1183/13993003/erj.38.suppl_55.p500

View Full Paper

Ask AI

Bookmark

Implication

Observational study shows that substituting ACE-I with telmisartan significantly reduces dry cough in hypertensive patients, indicating improved tolerability.

Cough among hypertensive patients treated with angiotensin convertase inhibitors. Reduction of its frequency by substitution of angiotensin convertase inhibitor with angiotensin receptor blocker. Results of non-interventional, observational postmarketing study

Discussion

Member takes

Implication

Key Points

Cite This Study

Cough among hypertensive patients treated with angiotensin convertase inhibitors. Reduction of its frequency by substitution of angiotensin convertase inhibitor with angiotensin receptor blocker. Results of non-interventional, observational postmarketing study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider